Wed, Mar 4, 2015, 4:19 AM EST - U.S. Markets open in 5 hrs 11 mins


% | $
Quotes you view appear here for quick access.

Affymax, Inc. (AFFY) Message Board

scanit2008 6 posts  |  Last Activity: 11 hours ago Member since: Feb 4, 2008
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • On the sidelines now.

    To whoever sold me their shares and to whoever bought my shares I say "thank you very much".

    Made my week and it's only Tuesday.

  • scanit2008 by scanit2008 Feb 19, 2015 8:42 AM Flag

    If you invest in bio-tech you should consider Amarantus Bioscience -AMBS - currently under a dime.

    The company recently launched its diagnostic test, LymPro, that detects early stage Alzheimer's. Potential $3B annual market.

    The company also has several orphan indications for its patented drug MANF.

    Read yesterday's Yahoo news for AMBS.

    Twitter: @AmarantusBio

  • Reply to

    Something To Consider

    by scanit2008 Jan 21, 2015 9:21 AM
    scanit2008 scanit2008 Jan 22, 2015 1:56 PM Flag

    Read today's Yahoo news.

  • Reply to

    Can You Spare A Dime?

    by scanit2008 Jan 21, 2015 11:03 AM
    scanit2008 scanit2008 Jan 22, 2015 1:56 PM Flag

    Read today's Yahoo news.

  • Reply to

    10,200 Followers on Twitter

    by aunttizzy Jan 21, 2015 9:25 AM
    scanit2008 scanit2008 Jan 22, 2015 9:48 AM Flag

    Amarantus Forms Alzheimer's Disease Diagnostics Scientific Advisory Board

    SAN FRANCISCO and GENEVA, Jan. 22, 2015 (GLOBE NEWSWIRE) -- Amarantus BioScience Holdings, Inc. (AMBS), a biotechnology company focused on developing diagnostics in neurology, and therapeutic products in the areas of neurology, psychiatry, ophthalmology and regenerative medicine, announced that it has established an Alzheimer's disease Diagnostics Scientific Advisory Board (SAB) and appointed three internationally-renowned specialists in Alzheimer's disease (AD) and neurological disorders, Paula T. Trzepacz, M.D., Jeffrey L. Cummings, M.D., Sc.D., and Robert A. Stern, Ph.D., as its first members. The company expects to expand the SAB during the first half of 2015.

    "I am pleased to announce the appointments of such an esteemed trio of Alzheimer's researchers to Amarantus Diagnostics' inaugural Scientific Advisory Board," said Gerald E. Commissiong, President & CEO of Amarantus. "Following last week's announcement of our exclusive option agreement with Georgetown University to license their suite of markers for Alzheimer's disease, adding exciting lipidomic and exosome modalities to our cell cycle dysregulation LymPro Test(R) blood diagnostic, we are now positioned to corner the entire Alzheimer's blood-based diagnostics marketplace, a potential $3 billion market opportunity. We are beginning with the $150 million Investigational Use Only (IUO) market by offering the world's most extensive suite of markers to the pharmaceutical industry.

    "I am particularly impressed with the extensive neurobiology and neurotherapeutic experience of our inaugural members in Alzheimer's disease given that we are now actively engaged in the marketing of our blood-based markers to the IUO market. They will be of great assistance as we work with pharmaceutical companies to improve their Alzheimer's therapeutics development progr

  • scanit2008 by scanit2008 Jan 21, 2015 12:26 PM Flag

    $AMBS - Launching First Diagnostic Blood Test to Detect Alzheimer's

    Currently trading under a dime. 300-500% upside this year.

    Read the recent Yahoo news.

    Dr. Joseph Rubinfeld, one of the co-founders of Amgen, recently joined the company's B.O.D.

    Twitter: @AmarantusBio .... 10,200 followers.

0.1475+0.0200(+1.67%)Mar 3 3:41 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.